Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20496737 | 0.83 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL82327 | 0.78 | TSHR (0.37) | — | |
| SCHEMBL8096900 | 0.77 | EPHX1 (0.32) | EPHX1CHRNB2CHRNA4 | |
| SCHEMBL8839156 | 0.76 | MEN1 (0.33) | — | |
| SCHEMBL2702039 | 0.76 | LMNA (0.35) | — | |
| SCHEMBL11028041 | 0.76 | TSHR (0.37) | — | |
| SCHEMBL4412389 | 0.76 | TSHR (0.36) | — | |
| SCHEMBL1071091 | 0.76 | MGAM (0.45) | — | |
| SCHEMBL28379558 | 0.74 | — | — | |
| SCHEMBL4312022 | 0.74 | HCAR2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336856-B2 | Alkoxysilane- and allophanate-functionalized coating materials | EVONIK DEGUSSA GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-10336854-B2 | Alkoxysilane-functionalized and allophanate-functionalized urethanes | EVONIK DEGUSSA GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-10093826-B2 | Alkoxysilane-functionalized allophanate-containing coating compositions | EVONIK DEGUSSA GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| US-10093765-B2 | Alkoxysilane-functionalized allophanates | EVONIK DEGUSSA GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| US-20170369736-A1 | ALKOXYSILANE-FUNCTIONALIZED ALLOPHANATE-CONTAINING COATING COMPOSITIONS | EVONIK DEGUSSA GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| US-20170369631-A1 | ALKOXYSILANE- AND ALLOPHANATE-FUNCTIONALIZED COATING MATERIALS | EVONIK DEGUSSA GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| US-20170369627-A1 | ALKOXYSILANE-FUNCTIONALIZED AND ALLOPHANATE-FUNCTIONALIZED URETHANES | EVONIK DEGUSSA GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| US-20170369626-A1 | ALKOXYSILANE-FUNCTIONALIZED ALLOPHANATES | EVONIK DEGUSSA GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336856-B2 | Alkoxysilane- and allophanate-functionalized coating materials | DDAH1, OR10J3, AP3S1 | EPHX1 2768/4885CHRNB2 1125/4885CHRNA4 1955/4885 |
| US-20170369626-A1 | ALKOXYSILANE-FUNCTIONALIZED ALLOPHANATES | OR10J3, NOS3, NOX3 | EPHX1 1939/4885CHRNB2 1114/4885CHRNA4 1502/4885 |
| US-10093826-B2 | Alkoxysilane-functionalized allophanate-containing coating compositions | DDAH1, OR10J3, AP3S1 | EPHX1 3064/4885CHRNB2 637/4885CHRNA4 1210/4885 |
| US-10093765-B2 | Alkoxysilane-functionalized allophanates | OR10J3, NOS3, NOX3 | EPHX1 1939/4885CHRNB2 1114/4885CHRNA4 1502/4885 |
| US-10336854-B2 | Alkoxysilane-functionalized and allophanate-functionalized urethanes | ALKBH3, PUF60, SDC2 | EPHX1 1685/4885CHRNB2 1703/4885CHRNA4 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.